Oct. 8 at 12:31 AM
OS Therapies (NYSE American:
$OSTX) announced an extensive fall conference schedule alongside two Emmy Award nominations for âShelter Me: Cancer Pioneers,â a PBS documentary exploring how canine osteosarcoma research advances treatments for human patients, particularly children.
OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://b2idigital.com/os-therapies-1.
October/November Conference & Event Schedule:
⢠Cell and Gene Meeting on the Mesa (October 6-8, Phoenix, AZ) - Partnering meetings with Paul Romness, Chairman & CEO https://meetingonthemesa.com/
⢠Roth Annual Healthcare Opportunities Conference (October 9, New York City) - Gerald Commissiong, Chief Business Officer conducting meetings https://www.meetmax.com/sched/event_123727/conference_home.html
⢠FDA/OSI Workshop on Advancing Osteosarcoma Drug Development (October 10, Washington, DC) - Meeting participation and availability for sideline discussions https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fdathe-osteosarcoma-institute-osi-workshop-advancing-osteosarcoma-drug-development-connecting
⢠BIOFuture 2025 (October 13-15, New York City) - Spotlight panel and meetings with Gerald Commissiong https://biofuture.com/
⢠52nd Daytime Emmy Awards (October 17, Pasadena, CA) - âShelter Me: Cancer Pioneersâ nominated for 2 Emmy Awards, featuring clinicians, veterinarians, and human & canine patients from OST-HER2 clinical trials https://watch.theemmys.tv/
⢠Maxim Growth Summit: Maxim Group Healthcare Conference (October 22, New York City) - Corporate presentation with Paul Romness and Gerald Commissiong https://www.maximgrp.com/2025-growth-summit
⢠BIO-Europe (November 3-5, Vienna, Austria) - International partnering meetings with Paul Romness https://informaconnect.com/bioeurope/
See the full release at https://ir.ostherapies.com/news-events/press-releases/detail/83/os-therapies-to-participate-in-fall-2025-conferences-and
Led by CEO Paul Romness and an experienced executive team including Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is advancing its pipeline for osteosarcoma and other hard-to-treat cancers.
Learn more about OS Therapiesâ work at https://www.ostherapies.com and visit B2i Digital for updates. For investor-related questions, please see OS Therapiesâ Investor Relations page or email
[email protected].
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted OSTX stock, in line with B2i Digitalâs practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of OSTX or any security, and it is not intended to offer any opinion on OSTX as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions.
